What Is Orforglipron? The First Oral GLP-1 Pill for Weight Loss

Orforglipron, sold under the brand name Foundayo, is a once-daily GLP-1 pill for weight loss from Eli Lilly, and it reached a milestone in April 2026 when the FDA approved it for adults with obesity, or overweight with a weight-related medical condition. Unlike injectable GLP-1 medications, orforglipron is a small-molecule tablet, and unlike the oral semaglutide pill, it can be taken any time of day without restrictions on food or water. In its main trial, the highest dose produced average weight loss of about 11% to 12% of body weight over 72 weeks. It’s the newest oral option in a field long dominated by injections.

Why an oral GLP-1 matters

Injectable GLP-1 drugs like semaglutide and tirzepatide are highly effective, but injections are a barrier for some people, whether due to needle aversion, convenience, or storage. A pill that delivers meaningful weight loss removes one of those obstacles.

Orforglipron isn’t the first oral GLP-1 for weight management (an oral form of semaglutide was approved in December 2025), but it has a practical advantage: oral semaglutide must be taken in the morning on an empty stomach with a small amount of water, then you wait before eating or drinking. Orforglipron has no such requirement, which makes it easier to fit into daily life.

How it works

Orforglipron is a non-peptide GLP-1 receptor agonist. Like other GLP-1 drugs, it reduces appetite, increases fullness, and slows stomach emptying, which together lower how much you eat. What’s different is its chemistry: being a small molecule, it can be manufactured as a stable tablet and absorbed without the strict conditions peptide-based oral drugs require.

What the trial data shows

The pivotal evidence comes from the ATTAIN-1 trial published in the New England Journal of Medicine in 2025, which studied 3,127 adults with obesity or overweight and a related condition, without diabetes. Over 72 weeks, the highest dose (36 mg) produced average weight loss of about 11% to 12%, with more than half of participants on that dose losing at least 10% of their body weight, alongside improvements in cardiometabolic measures.

Dosing, cost, and side effects

Foundayo comes in six doses, starting low and increasing gradually to reduce side effects. Self-pay pricing starts around $149 per month for the lowest dose, with higher doses costing more, and eligible people with commercial insurance may pay less with a savings card.

The most common side effects are gastrointestinal (nausea, constipation, diarrhea, vomiting, abdominal pain), consistent with the GLP-1 class, plus headache and hair loss in some people. It carries a boxed warning regarding thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid carcinoma or the genetic condition MEN 2. It may also make oral birth control less effective, so that’s worth discussing with a provider.

Common questions

Is orforglipron the same as Foundayo?

Yes. Orforglipron is the drug’s generic name, and Foundayo is Eli Lilly’s brand name for it.

How much weight can you lose on orforglipron?

In its main trial, the highest dose produced average weight loss of about 11% to 12% over 72 weeks, though individual results vary.

Is it as effective as injections?

Injectable semaglutide produced somewhat more weight loss in trials (around 15%), and tirzepatide more still. Orforglipron’s appeal is convenience: comparable class of benefit in a flexible daily pill.

The bottom line

Orforglipron (Foundayo) is a real step forward for people who prefer a pill, offering meaningful weight loss without the timing rules of earlier oral options. Whether it or an injectable option fits you best depends on your goals, tolerability, and health history. You can see which treatments you’re a candidate for through TrimRx’s quiz and get guidance from a licensed provider.

This information is for educational purposes and is not medical advice. Consult a healthcare provider before starting any medication. Individual results may vary.